TAMMY WOLVERTON: Open Payments
NPI 1770139586 · ANDERSON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$653 in 30 payments from 10 companies in 2025. Trend: 2023 $299 · 2024 $225 · 2025 $653
Food & beverage: $653
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $346 |
| Teva Pharmaceuticals USA, Inc. | 5 | $103 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
| Neos Therapeutics, LP | 1 | $22 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Corium, LLC | 1 | $17 |
Products named: LYBALVI, ARISTADA, UZEDY, AUSTEDO XR, CAPLYTA, FANAPT, Adzenys XR-ODT, ERZOFRI EXTENDED-RELEASE.
Industry payments across IN — which companies pay providers there.
